Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2052 ARTÍCULOS , VIENDO DEL 106 AL 120

Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's disease

Bera A, Lavanya G, Reshmi R, Dev K, Kumar R.

Eur J Neurosci. 2022 Nov;56(9):5516-5531. doi: 10.1111/ejn.15611. Epub 2022 Feb 12.

Functional insight into LOAD-associated microglial response genes

Jonas LA, Jain T, Li YM.

Open Biol. 2022 Jan;12(1):210280. doi: 10.1098/rsob.210280. Epub 2022 Jan 26.

Protein degradation-associated mechanisms that are affected in Alzheimer´s disease

Tecalco-Cruz AC, Pedraza-Chaverri J, Briones-Herrera A, Cruz-Ramos E, López-Canovas L, Zepeda-Cervantes J.

Mol Cell Biochem. 2022 Mar;477(3):915-925. doi: 10.1007/s11010-021-04334-8. Epub 2022 Jan 27.

Tau protein aggregation: Key features to improve drug discovery screening

Giovannini J, Smeralda W, Jouanne M, Sopkova-de Oliveira Santos J, Catto M, Voisin-Chiret AS.

Drug Discov Today. 2022 May;27(5):1284-1297. doi: 10.1016/j.drudis.2022.01.009. Epub 2022 Jan 24.

Revisiting APP secretases: an overview on the holistic effects of retinoic acid receptor stimulation in APP processing

Vitória JJM, Trigo D, da Cruz E Silva OAB.

Cell Mol Life Sci. 2022 Jan 28;79(2):101. doi: 10.1007/s00018-021-04090-4.

Advances in prodrug design for Alzheimer's disease: the state of the art

Travers-Lesage V, Mignani SM, Dallemagne P, Rochais C.

Expert Opin Drug Discov. 2022 Apr;17(4):325-341. doi: 10.1080/17460441.2022.2031972. Epub 2022 Feb 23.

Brain-derived neurotrophic factor in Alzheimer's disease and its pharmaceutical potential

Gao L, Zhang Y, Sterling K, Song W.

Transl Neurodegener. 2022 Jan 28;11(1):4. doi: 10.1186/s40035-022-00279-0.

Regulatory decisions diverge over aducanumab for Alzheimer's disease

Lythgoe MP, Jenei K, Prasad V.

BMJ. 2022 Jan 28;376:e069780. doi: 10.1136/bmj-2021-069780.

Do glutathione and copper interact to modify Alzheimer's disease pathogenesis?

Ho T, Ahmadi S, Kerman K.

Free Radic Biol Med. 2022 Mar;181:180-196. doi: 10.1016/j.freeradbiomed.2022.01.025. Epub 2022 Jan 29.

Alzheimer's disease therapy based on acetylcholinesterase inhibitor/blocker effects on voltage-gated potassium channels

Li XT.

Metab Brain Dis. 2022 Mar;37(3):581-587. doi: 10.1007/s11011-022-00921-w. Epub 2022 Jan 31.

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial

Gonzales MM, Garbarino VR, Marques Zilli E, Petersen RC, Kirkland JL, Tchkonia T, Musi N, Seshadri S, Craft S, Orr ME.

J Prev Alzheimers Dis. 2022;9(1):22-29. doi: 10.14283/jpad.2021.62.

Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer's disease: a systematic review and meta-analysis

Wang H, Zong Y, Han Y, Zhao J, Liu H, Liu Y.

Expert Opin Drug Saf. 2022 Mar;21(3):407-415. doi: 10.1080/14740338.2022.2027905. Epub 2022 Jan 31.

Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review

Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F.

JAMA Neurol. 2022 Mar 1;79(3):291-304. doi: 10.1001/jamaneurol.2021.5205.

Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial

Vila-Castelar C, Tariot PN, Sink KM, Clayton D, Langbaum JB, Thomas RG, Chen Y, Su Y, Chen K, Hu N, Giraldo-Chica M, Tobón C, Acosta-Baena N, Luna E, Londoño M, Ospina P, Tirado V, Muñoz C, Henao E, Bocanegra Y, Alvarez S, Rios-Romenets S, Ghisays V, Goradia D, Lee W, Luo J, Malek-Ahmadi MH, Protas HD, Lopera F, Reiman EM, Quiroz YT; API ADAD Colombia Trial Group.

Alzheimers Dement. 2022 Nov;18(11):2272-2282. doi: 10.1002/alz.12552. Epub 2022 Feb 1.

Developing a pathway to support the appropriate, affordable, and widespread use of effective Alzheimer's prevention drugs

Reiman EM, Mattke S, Kordower JH, Khachaturian ZS, Khachaturian AS.

Alzheimers Dement. 2022 Jan;18(1):7-9. doi: 10.1002/alz.12533. Epub 2022 Feb 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias